Diagnostic Histopathology
Volume 15, Issue 3 , Pages 134-141 , March 2009

Plasma cell neoplasms

References 

  1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962–2972
  2. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757
  3. McKenna R, Kyle R, Kuehl W, Grogan T, Harris N, Coupland R. Plasma cell neoplasms. In:  Swerdlow SH,  Elias C,  Harris NL editor. WHO classifiation of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008;p. 200–213
  4. Rajkumar SV, Greipp PR. Angiogenesis in multiple myeloma. Br J Haematol. 2001;113:565
  5. Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol. 1987;87:342–355
  6. Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology - an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91:2501–2507
  7. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473
  8. Snozek CL, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 2008;22:1933–1937
  9. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785–789
  10. Jakob C, Sterz J, Liebisch P, et al. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia. 2008;22:1812
  11. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482–488
  12. Mateo G, Montalban MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008;26:2737–2744
  13. Bergsagel PL, Smith AM, Szczepek A, Mant MJ, Belch AR, Pilarski LM. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood. 1995;85:436–447
  14. Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR, Pilarski LM. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood. 1998;92:2844–2855
  15. Wilson CS, Butch AW, Lai R, et al. Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy. Br J Haematol. 2001;112:776–782
  16. Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ. The (11;14) (q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol. 2000;113:831–837
  17. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol. 2007;20:571–596
  18. Li ZW, Chen H, Campbell RA, Bonavida B, Berenson JR. NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol. 2008;15:391–399
  19. Yasui H, Hideshima T, Richardson PG, Anderson KC. Recent advances in the treatment of multiple myeloma. Curr Pharm Biotechnol. 2006;7:381–393
  20. Anargyrou K, Dimopoulos MA, Sezer O, Terpos E. Novel anti-myeloma agents and angiogenesis. Leuk Lymphoma. 2008;49:677–689
  21. Hideshima T, Raje N, Richardson PG, Anderson KC. A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag. 2008;4:129–136
  22. Mateos MV, San Miguel JF. Bortezomib in multiple myeloma. Best Pract Res Clin Haematol. 2007;20:701–715
  23. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–3420
  24. Chng WJ, Kuehl WM, Bergsagel PL, Fonseca R. Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia. 2008;22:459–461
  25. Soutar R, Lucraft H, Jackson G, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124:717–726
  26. Pellat-Deceunynck C, Barille S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12:1977–1982
  27. Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22:1044–1052
  28. Rajkumar SV, Lacy MQ, Kyle RA. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev. 2007;21:255–265
  29. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am. 2007;21:1093–1113ix
  30. Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol. 2007;20:637–664
  31. Hardin J, Waddell M, Page CD, et al. Evaluation of multiple models to distinguish closely related forms of disease using DNA microarray data: an application to multiple myeloma. Stat Appl Genet Mol Biol. 2004;3:Article 10
  32. Gertz MA, Rajkumar SV. Primary systemic amyloidosis. Curr Treat Options Oncol. 2002;3:261–271
  33. Rajkumar SV, Gertz MA. Advances in the treatment of amyloidosis. N Engl J Med. 2007;356:2413–2415
  34. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis. Best Pract Res Clin Haematol. 2005;18:709–727
  35. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem. 2005;51:878–881
  36. Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am. 1999;13:1235–1248
  37. Gokden N, Barlogie B, Liapis H. Morphologic heterogeneity of renal light-chain deposition disease. Ultrastruct Pathol. 2008;32:17–24

PII: S1756-2317(09)00023-1

doi: 10.1016/j.mpdhp.2009.01.009

Diagnostic Histopathology
Volume 15, Issue 3 , Pages 134-141 , March 2009

Article Tools

* Image Usage & Resolution